Impact of Timing of Achievement of Red Blood Cell-Transfusion Independence (RBC-TI) on Clinical Outcomes and Resource Utilization in Lower-Risk Myelodysplastic Syndromes (LR-MDS)

被引：0

作者：

Coughlan, Anna ^{[1
]}

Klijn, Sven L. ^{[2
]}

Xiao, Hong ^{[3
]}

White, Benjamin ^{[4
]}

Litkiewicz, Michal ^{[5
]}

Kadambi, Ananth ^{[4
]}

Sichevaya, Alina

Hnoosh, Ahmed ^{[6
]}

Miteva, Dimana ^{[7
]}

Yucel, Aylin ^{[3
]}

机构：

[1] Evidera, Bethesda, MD USA

[2] Bristol Myers Squibb, Lawrence, NJ USA

[3] Bristol Myers Squibb, Princeton, NJ USA

[4] Evidera, San Francisco, CA USA

[5] Evidera, London, England

[6] Evidera, London, England

[7] Bristol Myers Squibb Co, Celgene Int Sarl, Boudry, Switzerland

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

myelodysplastic syndromes; transfusion independence; burden of illness;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MDS-008

引用

页码：S351 / S351

页数：1

共 50 条

[31] Durable Continuous Transfusion Independence (TI) with Imetelstat in IMerge Phase 3 for Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to or Ineligible for Erythropoiesis-Stimulating Agents (ESAs)
Platzbecker, Uwe
Komrokji, Rami S.
Zeidan, Amer M.
Fenaux, Pierre
Sekeres, Mikkael A.
Savona, Michael R.
Madanat, Yazan F.
Jonasova, Anna
Illmer, Thomas
Sherman, Laurie
Berry, Tymara
Riggs, Jennifer
Xia, Qi
Navada, Shyamala
Wan, Ying
Huang, Fei
Feller, Faye M.
Santini, Valeria
BLOOD, 2023, 142
[32] Persistent Red Blood Cell (RBC) Transfusion Is Associated with Increased Mortality Risk in Transfusion-Dependent (TD) Patients with Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS plus )
Buckstein, Rena
Zhu, Nancy
Keating, Mary-Margaret
Leber, Brian
Chodirker, Lisa
Sabloff, Mitchell
Cristou, Grace
Leitch, Heather A.
St Hilaire, Eve
Finn, Nicholas
Yee, Karen W. L.
Elemary, Mohamed
Banerji, Versha
Lenis, Martha
Kirubananthaan, Aksharh
Liu, Fei Fei
Tang, Derek
Westcott, Chris
Huang, Vicky Wei-Hsuen
Wang, Di
Cameron, Chris
Morison, Jessica
Spin, Paul
Mamedov, Alexandre
BLOOD, 2019, 134
[33] THE IMPACT OF IRON CHELATION THERAPY ON CLINICAL OUTCOMES IN REAL-WORLD LOWER-RISK PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS): RESULTS FROM THE DUSSELDORF REGISTRY
Neukirchen, J.
Germing, U.
Fox, F.
Glaser, S.
Gattermann, N.
HAEMATOLOGICA, 2012, 97 : 144 - 144
[34] Red Blood Cell Transfusion Dependence Is Associated with Greater Healthcare Resource Utilization, Higher Medical Cost, and Poorer Prognosis in Patients with Lower-Risk Myelodysplastic Syndromes: A 28-Year Retrospective Observation Study Result
Jang, Jun Ho
Kim, Ji-Hyun
Lee, Kyungah
Kim, Eugene
Kim, Hyojin
Wang, Fangyuan
BLOOD, 2023, 142
[35] Patient-Reported Outcomes (PRO) of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive, Transfusion-Dependent (TD), Lower-Risk Myelodysplastic Syndromes (LR-MDS): Results from the Phase 3 COMMANDS Study
Oliva, Esther Natalie
Platzbecker, Uwe
Della Porta, Matteo Giovanni
Garcia-Manero, Guillermo
Santini, Valeria
Fenaux, Pierre
Shortt, Jake
Komrokji, Rami S.
Pelligra, Christopher
Guo, Shien
Lord-Bessen, Jennifer
Xiao, Hong
Yucel, Aylin
Miteva, Dimana
Rose, Shelonitda
Kreitz, Sandra
Sekeres, Mikkael A.
Zeidan, Amer M.
BLOOD, 2023, 142
[36] Luspatercept versus epoetin alfa (EA) for treatment (tx) of anemia in ESA-naive lower-risk myelodysplastic syndromes (LR-MDS) patients (pts) requiring RBC transfusions (RBCT): data from the phase 3 COMMANDS study
Platzbecker, Uwe
Porta, Matteo Giovanni
Santini, Valeria
Zeidan, Amer M.
Fenaux, Pierre
Komrokji, Rami S.
Shortt, Jake
Valcarcel, David
Jonasova, Anna
Dimicoli-Salazar, Sophie
Tiong, Ing Soo
Lin, Chien-Chin
Li, Jiahui
Zhang, Jennie
Giuseppi, Ana Carolina
Kreitz, Sandra
Pozharskaya, Veronika
Keeperman, Karen L.
Rose, Shelonitda
Shetty, Jeevan K.
Hayati, Sheida
Vodala, Sadanand
Degulys, Andrius
Paolini, Stefania
Cluzeau, Thomas
Garcia-Manero, Guillermo
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 116 - 116
[37] Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial
Garcia-Manero, Guillermo
Platzbecker, Uwe
Santini, Valeria
Zeidan, Amer M.
Fenaux, Pierre
Komrokji, Rami S.
Shortt, Jake
Valcarcel, David
Jonasova, Anna
Dimicoli-Salazar, Sophie
Tiong, Ing Soo
Lin, Chien-Chin
Li, Jiahui
Zhang, Jennie
Giuseppi, Ana Carolina
Kreitz, Sandra
Pozharskaya, Veronika
Keeperman, Karen L.
Rose, Shelonitda
Prebet, Thomas
Degulys, Andrius
Paolini, Stefania
Cluzeau, Thomas
Della Porta, Matteo Giovanni
BLOOD, 2023, 142
[38] Luspatercept Reduces Red Blood Cell Transfusions (RBCT) in Patients with Lower-Risk Myelodysplastic Syndromes (LRMDS) Regardless of Baseline Transfusion Burden (TB) in the MEDALIST Study
Platzbecker, Uwe
Garcia-Manero, Guillermo
Fenaux, Pierre
Buckstein, Rena
Santini, Valeria
Diez-Campelo, Maria
Tang, Derek
Ito, Rodrigo
Fabre, Shannon
Mantovani, Emily
Zoffoli, Roberto
Miteva, Dimana
Hughes, Christina
Khan, Wasiulla
Komrokji, Rami S.
Germing, Ulrich
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 142 - 142
[39] Efficacy and safety of luspatercept versus epoetin alfa (EA) in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with transfusion-dependent (TD) lower-risk myelodysplastic syndromes (LR-MDS): full analysis of the COMMANDS trial
Platzbecker, Uwe
Garcia-Manero, Guillermo
Santini, Valeria
Zeidan, Amer M.
Fenaux, Pierre
Komrokji, Rami S.
Shortt, Jake
Valcarcel, David
Jonasova, Anna
Dimicoli-Salazar, Sophie
Tiong, Ing Soo
Lin, Chien-Chin
Li, Jiahui
Zhang, Jennie
Giuseppi, Ana Carolina
Kreitz, Sandra
Pozharskaya, Veronika
Keeperman, Karen L.
Rose, Shelonitda
Prebet, Thomas
Degulys, Andrius
Paolini, Stefania
Cluzeau, Thomas
Porta, Matteo Giovanni
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 243 - 243
[40] Reduction of Transfusion Burden (TB), Hemoglobin Increase, and Dose Titration in the COMMANDS Study of Luspatercept Versus Epoetin Alfa (EA) in Erythropoietin-Stimulating Agent (ESA)-Naive Patients With Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Komrokji, Rami S.
Platzbecker, Uwe
Della Porta, Matteo
Santini, Valeria
Garcia-Manero, Guillermo
Li, Jiahui
Zhang, Jennie
Giuseppi, Ana Carolina
Kreitz, Sandra
Pozharskaya, Veronika
Keeperman, Karen L.
Rose, Shelonitda
Hughes, Christina
Valcarcel, David
Fenaux, Pierre
Shortt, Jake
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S358 - S359

← 1 2 3 4 5 →